Cardiac problems associated with vascular endothelial growth factor inhibitors occur frequently in patients with cancer.

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

A study demonstrates the role of the Galectin-1 protein in the nucleus of the cells surrounding the tumor -- fibroblasts -- contributing to their activation. Activated fibroblasts promote tumor growth ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates-only 10% after five years.

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

These biologics, which include monoclonal antibodies, cancer growth inhibitors, gene therapies, and vaccines, among others, have revolutionized the way cancer is treated. The significance of the ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally ...